Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts ...

Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

Major stock indexes closed lower on Friday, after the week saw a flurry of events, including DeepSeek scare and earnings ...

RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...

While the revised outlook appears feasible, it "leads us to believe MRNA has limited visibility on the revenue stream for the respiratory vaccine business," analyst Salveen Richter wrote ...

The stock has dropped 56% over the last 12 months. Analysts led by Salveen Richter lowered Moderna's rating to neutral from buy as they say Moderna has limited visibility on the revenue stream for ...

Apellis Pharmaceuticals (APLS – Research Report) received a Hold rating and price target from Goldman Sachs analyst Salveen Richter today. The company’s shares closed yesterday at $33.66.